Amendment No.1 to Schedule 13G

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Av2QxJYzbD3xYxNeK1aqQJcrlMyDq/Jx2XLJh6RYG43UniY51PH9+bm24iQPlykZ ex07W+6zmo3FMvGCHWgcEQ== 0001193125-04-079147.txt : 20040505 0001193125-04-079147.hdr.sgml : 20040505 20040505144407 ACCESSION NUMBER: 0001193125-04-079147 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040505 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41938 FILM NUMBER: 04781114 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 BUSINESS PHONE: 805-447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE STREET 2: MAIL STOP 27-3-C CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 SC 13G/A 1 dsc13ga.htm AMENDMENT NO.1 TO SCHEDULE 13G Amendment No.1 to Schedule 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

REGENERON PHARMACEUTICALS, INC.

(Name of Issuer)

COMMON STOCK, $.001 PAR VALUE

(Title of Class of Securities)

00075886F1

(CUSIP Number)

March 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 00075886F1		13G		Page 2 of 6 Pages



1.		Name of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Amgen Inc.

2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨

3.		SEC Use Only

4.		Citizenship or Place of Organization Delaware

NUMBER OF

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5. Sole Voting Power

3,181,309

6. Shared Voting Power

N/A

7. Sole Dispositive Power

3,181,309

8. Shared Dispositive Power

N/A


9.		Aggregate Amount Beneficially Owned by Each Reporting Person 3,181,309

10.		Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) N/A

11.		Percent of Class Represented by Amount in Row (9) 6.0%

12.		Type of Reporting Person (See Instructions) CO


CUSIP No. 00075886F1		13G		Page 3 of 6 Pages

This Amendment No. 1 to Schedule 13G is being filed by Amgen Inc., a Delaware corporation (the “Reporting Person”), to amend and supplement the Schedule 13G filed on February 4, 2002 and Schedule 13D filed on July 26, 1995, as amended by Amendment No. 1 filed on September 25, 1995, Amendment No. 2 filed on December 6, 1995, Amendment No. 3 filed on March 5, 1996, Amendment No. 4 filed on April 15, 1996, Amendment No. 5 filed on March 7, 2000, Amendment No. 6 filed on April 5, 2000, Amendment No. 7 filed on March 13, 2001 and Amendment No. 8 filed on March 22, 2001 (the “Schedule 13D”), relating to the common stock, $.001 par value per share (the “Common Stock”) of Regeneron Pharmaceuticals, Inc. (the “Issuer”). Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the meaning assigned to them in the Schedule 13D.

Sales of 750,000 shares of Common Stock of the Issuer were made prior to February 14, 2004. Sales of 250,000 shares of Common Stock of the Issuer have been made since February 14, 2004. All sales were made pursuant to the divestiture requirements of the July 12, 2002 Decision and Order of the Federal Trade Commission In the Matter of Amgen Inc. and Immunex Corporation.

Item 1

(a).

Name of Issuer:

Regeneron Pharmaceuticals, Inc.

Item 1

(b).

Address of Issuer’s Principal Executive Offices:

777 Old Saw Mill River Road

Tarrytown, New York 10591-6707

Item 2

(a).

Name of Person Filing:

Amgen Inc.

Item 2

(b).

Address of Principal Business Office or, if None, Residence:

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

Item 2

(c).

Citizenship:

Delaware

Item 2

(d).

Title of Class of Securities:

Common Stock, par value $0.001 per share (the “Common Stock”)


CUSIP No. 00075886F1		13G		Page 4 of 6 Pages

Item 2

(e).

CUSIP Number:

00075886F1

Item 3.

Not applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned: 3,181,309

(b)

Percent of class:

Amgen Inc. may be deemed the beneficial owner of approximately 6.0% of the outstanding shares of the Common Stock. The calculation of the percentage is based on the number of shares of the Common Stock shown as being outstanding on the Form 10-K Annual Report filed by Regeneron Pharmaceuticals, Inc. with the Securities and Exchange Commission for the year ended December 31, 2003.

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote: 3,181,309

(ii)

Shared power to vote or to direct the vote: None

(iii)

Sole power to dispose or to direct the disposition of: 3,181,309

(iv)

Shared power to dispose or to direct the disposition of: None

Item 5.

Not applicable.

Item 6.

Not applicable.

Item 7.

Not applicable.

Item 8.

Not applicable.

Item 9.

Not applicable.


CUSIP No. 00075886F1		13G		Page 5 of 6 Pages



Item 10.		Certification.

		By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


CUSIP No. 00075886F1		13G		Page 6 of 6 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: May 5, 2004

AMGEN INC.

By:		/s/ David J. Scott

Name:		David J. Scott
Title:		Senior Vice President, General Counsel and Secretary

-----END PRIVACY-ENHANCED MESSAGE-----